Citations

Clear

396 citation(s) found for "Spinner, M".

Outcomes of classic Hodgkin lymphoma, relapsed within one year of diagnosis, in the era of novel agents.
David, Kevin A. , Saba, Raya , Dorritie, Kathleen , Harris, Elyse I., Fusco, Brendon , Hatic, Haris, Iyengar, Siddharth , Rappazzo, Katherine , Micallef, Ivana N. , Desai, Sanjal H. , Spinner, Michael A. , Bachanová, Veronika , Goyal, Gaurav , Azzi, Jacques Mario , Sumransub, Nuttavut , Ibrahim, Uroosa , Baidoun, Firas , Orellana‐Noia, Victor M. , Diefenbach, Catherine , Advani, Ranjana H.

Mayo Clinic

Journal of Clinical Oncology | June 6, 2022 | Volume: 40 | Issue: 16_suppl | Pages: 7515-7515

10.1200/jco.2022.40.16_suppl.7515 Get It

7515 Background: Primary refractory disease (PRD) and early relapse (ER) are predictors of poor prognosis in classic Hodgkin lymphoma (cHL). In this multicenter retrospective study, we describe outcomes of PRD and ER in pts with relapsed/refractory (R/R) cHL treated with salvage therapy (ST) and autologous stem cell transplant (ASCT). Methods: Of 14 sites, adult patients with R/R cHL who received ST and underwent ASCT were enrolled. PRD was defined as progression on frontline chemoimmunotherapy or within 6 months of diagnosis. ER was defined as relapse from 6 months-1 yr of diagnosis. Pts who relapsed >1 yr of diagnosis were called late relapses (LR). Study objectives were Overall response rates (ORR), CR rates, PFS, and OS. Results: Of 986 total pts, 160 had PRD, 365 had ER and 461 had LR. Significantly higher number of pts with PRD, but not ER, had bulky disease (41% vs 27%, p<0.01) and B symptoms (53% vs 38%, p<0.001) than LR. Higher proportions of pts with PRD and ER required >1 line of ST (44% vs 30% vs 23%, p<0.001) before ASCT and received BV maintenance (25% vs 24% vs 16%, p<0.05). When adjusted for B symptoms and Bulky disease, PRD and ER had significantly lower ORR (65% vs 76% vs 84%, p<0.001) and CR (37% vs 46% vs 57%, p<0.001) to first ST than LR. Pts with PRD and ER had significantly lower PFS (56.3%, 61.4%, vs 77.6%, p<.0001) and OS (93% vs 89% vs 94%, p=0.01) than LR. In pts with ER, Brentuximab/bendamustine (BBV) and brentuximab vedotin/nivolumab (BV/nivo) had a trend towards higher ORR (92% vs 92% vs 75%) but significantly higher CR (79.2% vs 76% vs 42%, p<0.01) than platinum based chemotherapy (PBC). In pts with PRD, BBV and BV/Nivo had a statistically insignificant trend towards higher ORR and CR than PBC. The table shows 2 yr PFS by type of ST in PRD, ER, LR. There was no difference in PFS by time to relapse in BV/nivo, CPI and miscellaneous agents. BV/Nivo had a significantly higher PFS than PBC in PRD (88% vs 48%, p<0.05) and ER (95% vs 57%, p<0.05). There was no difference in PFS of PBC and other ST in PRD, ER or LR. OS was not significantly associated with type of ST in either group. Conclusions: PRD and ER are associated with lower response to ST and survival after ASCT compared to late relapse. In pts with PRD and ER, BV/Nivo has high ORR and CR and leads to significantly higher PFS comparable to pts with late relapse and may be preferable ST regardless of time to relapse. [Table: see text]
Phase II trial of luspatercept with or without hydroxyurea for the treatment of patients with myelodysplastic/myeloproliferative neoplasms with ring sideroblasts and thrombocytosis or unclassifiable with ring sideroblasts.
Mangaonkar, Abhishek A. , Yi, Cecilia Ysabel Arana, Foran, James M. , Geyer, Susan M. , Lola, Erinayo S Baba, Hanson, Jean, Al‐Kali, Aref , Begna, Kebede H. , Elliott, Michelle A. , Gangat, Naseema , Litzow, Mark R. , Wolanskyj-Spinner, Alexandra P., Tefferi, Ayalew , Patnaik, Mrinal M. , Murthy, Hemant S. , Badar, Talha , McCullough, Kristen , Alkhateeb, Hassan B. , Shah, Meera , Wolanskyj, Alexandra P. , Hogan, William J.

Mayo Clinic

Journal of Clinical Oncology | June 6, 2022 | Volume: 40 | Issue: 16_suppl | Pages: TPS7080-TPS7080

10.1200/jco.2022.40.16_suppl.tps7080 Get It

TPS7080 Background: Myelodysplastic syndrome/myeloproliferative neoplasms (MDS/MPN) are classified as a distinct category under the World Health Organization (WHO) classification of myeloid neoplasms. MDS/MPN with RS and thrombocytosis (MDS/MPN-RS-T) and MDS/MPN, unclassifiable with > 15% bone marrow ring sideroblasts (MDS/MPN-U-RS) have similar clinical and pathological characteristics with symptomatic or transfusion-dependent anemia as the predominant morbidity. Luspatercept has been approved in myelodysplastic syndromes with ring sideroblasts (MDS-RS) and MDS/MPN overlap syndromes, based on the phase 3 MEDALIST clinical trial which primarily included MDS-RS patients with an objective erythroid response rate of approximately 40 per cent. In this trial, some MDS-RS patients also experienced an increase in neutrophil and platelet counts. This raises a safety concern for MDS/MPN patients with elevated platelet or WBC counts such as MDS/MPN-RS-T and MDS/MPN-U-RS. Previous studies have shown clinical and biological differences between MDS-RS and MDS/MPN-RS-T, with the latter group at a significantly elevated risk for thrombotic events. Additionally, several MDS/MPN-RS-T patients are on hydroxyurea which may blunt the erythroid response of luspatercept. Therefore, it is imperative to establish the safety and efficacy of luspatercept in this patient group. Methods: This is an investigator-initiated, prospective, phase II study of luspatercept in MDS/MPN overlap neoplasms with ring sideroblasts and thrombocytosis or unclassifiable with ring sideroblasts with 2 arms; hydroxyurea-independent (cohort A) and hydroxyurea-dependent (cohort B). Hydroxyurea and/or aspirin use is allowed as per investigator discretion. The primary goal is to study the efficacy and safety of luspatercept in MDS/MPN-RS-T or MDS/MPN-U-RS with symptomatic anemia. The primary endpoint is to assess erythroid response rate as per the 2015 International Working Group MDS/MPN response criteria. Secondary endpoints include response duration, time to acute myeloid leukemia (AML) transformation, thrombosis rate, AML-free and overall survival. Inclusion criteria include newly diagnosed or relapsed/refractory adult patients with WHO-defined diagnosis of MDS/MPN-RS-T or MDS/MPN-U-RS with symptomatic or transfusion-dependent anemia and unlikely to respond (EPO level > 200 IU/L) or intolerant to erythropoiesis stimulating agent (ESA) therapy. Prior therapy with lenalidomide, hypomethylating agents or immunosuppressive therapy is allowed. The overall plan is to enroll 54 patients across the three Mayo Clinic sites, Minnesota, Arizona and Florida. Enrollment to the trial began in January 2022 with 1 patient enrolled at the time of abstract submission. Clinical trial information: NCT05005182.
Management of neurofibromatosis type 1-associated plexiform neurofibromas
Fisher, Michael J. , Blakeley, Jaishri O. , Dombi, Eva , Akshintala, Srivandana , Belzberg, Allan J. , Bornhorst, Miriam , Bredella, Miriam A. , Ferner, Rosalie E. , Gross, Andrea M. , Harris, Gordon J. , Listernick, Robert , Ly, Ina , Martin, Staci , Mautner, Victor F., Salamon, Johannes, Salerno, Kilian , Spinner, Robert J. , Staedtke, Verena , Ullrich, Nicole J. , Upadhyaya, Meena , Wolters, Pamela L. , Widemann, Brigitte C. , Dombi, Eva , Bornhorst, Miriam , Blakeley, Jaishri O , Gross, Andrea M , Weiss, Brian , Ahlawat, Shivani , Cai, Wenli , Mautner, Victor‐F., Yohay, Kaleb

Mayo Clinic

Neuro-Oncology | June 3, 2022 | Volume: 24 | Issue: 11 | Pages: 1827-1844

10.1093/neuonc/noac146 | PMID 35657359 Get It

Abstract Plexiform Neurofibromas (PN) are a common manifestation of the genetic disorder neurofibromatosis type 1 (NF1). These benign nerve sheath tumors often cause significant morbidity, with treatment options limited historically to surgery. There have been tremendous advances over the past two decades in our understanding of PN, and the recent regulatory approvals of the MEK inhibitor selumetinib are reshaping the landscape for PN management. At present, there is no agreed upon PN definition, diagnostic evaluation, surveillance strategy, or clear indications for when to initiate treatment and selection of treatment modality. In this review, we address these questions via consensus recommendations from a panel of multidisciplinary NF1 experts.
Positive impact of the pandemic: the effect of post–COVID-19 virtual visit implementation on departmental efficiency and patient satisfaction in a quaternary care center
Pennington, Zach , Michalopoulos, Giorgos D. , Biedermann, Aaron, Ziegler, Jeffrey R., Durst, Sherri L., Spinner, Robert J. , Meyer, Fredric B. , Bydon, Mohamad , Pennington, Zach , Michalopoulos, Giorgos , Ziegler, Jeff R., Daniels, David J.

Mayo Clinic

Neurosurgical Focus | June 1, 2022 | Volume: 52 | Issue: 6 | Pages: E10

10.3171/2022.3.focus2243 | PMID 35921181 Get It

OBJECTIVE The coronavirus disease 2019 (COVID-19) pandemic has significantly changed clinical practice across US healthcare. Increased adoption of telemedicine has emerged as an alternative to in-person contact for patient-physician interactions. The aim of this study was to analyze the impact of telemedicine on workflow and care delivery from January 2019 to December 2021 in a neurosurgical department at a quaternary care center. METHODS Prospectively captured data on clinic appointment utilization, duration, and outcomes were queried. Visits were divided into in-person visits and telemedicine appointments, categorized as follow-up visits of previously surgically treated patients, internal consultations, new patient visits, and early postoperative returns after surgery. Appointment volume was compared pre- and postpandemic using March 2020 as the pandemic onset. Clinical efficiency was measured by time to appointment, rate of on-time appointments, proportion of appointments resulting in surgical intervention (surgical yield), and patient-reported satisfaction, the latter measured as the proportion of patients indicating “high likelihood to recommend practice.” RESULTS A total of 54,562 visits occurred, most commonly for follow-up for previously operated patients (51.8%), internal new patient referrals (24.5%), and external new patient referrals (19.8%). Total visit volume was stable pre- to postpandemic (1521.3 vs 1512, p = 0.917). However, in-person visits significantly decreased (1517/month vs 1220/month, p < 0.001), with a nadir in April 2020, while telemedicine appointment utilization increased significantly (0.3% vs 19.1% of all visits). Telemedicine utilization remained stable throughout the 1st calendar year following the pandemic. Telemedicine appointments were associated with shorter time to appointment than in-person visits both before and after the pandemic onset (0–5 days from appointment request: 60% vs 33% vs 29.8%, p < 0.001). Patients had on-time appointments in 87% of telemedicine encounters. Notably, telemedicine appointments resulted in surgery in 31.8% of internal consultations or new patient visits, a significantly lower rate than that for in-person visits (51.8%). After the widespread integration of telemedicine, patient satisfaction for all visits was higher than before the pandemic onset (85.9% vs 88.5%, p = 0.027). CONCLUSIONS Telemedicine use significantly increased following the pandemic onset, compensating for observed decreases in face-to-face visits. Utilization rates have remained stable, suggesting effective integration, and delays between referrals and appointments were lower than for in-person visits. Importantly, telemedicine integration was not associated with a decrease in overall patient satisfaction, although telemedicine appointments had a lower surgical yield. These data suggest that telemedicine smoothened the impact of the pandemic on clinical workflow and helped to maintain continuity and quality of outpatient care.
Intraneural ganglion cysts at the hip: The next celestial frontier
Spinner, Robert J. , Desy, Nicholas M. , Amrami, Kimberly K.

Mayo Clinic

Muscle & Nerve | May 26, 2022 | Volume: 66 | Issue: 3 | Pages: 236-239

10.1002/mus.27643 | PMID 35616442 Get It

See article on pages 339‐344 in this issue
Real-World Evidence of Sustained Improvement Following 60-day Peripheral Nerve Stimulation Treatment for Pain: A Cross-Sectional Follow-up Survey
Pingree, Matthew J. , Hurdle, Mark FB , Spinner, David, Valimahomed, Ali, Crosby, Nathan D. , Boggs, Joseph W. , Pingree, Matthew , Hurdle, Mark Friedrich , Crosby, Nathan D , Boggs, Joseph W

Mayo Clinic

Pain Management | May 5, 2022 | Volume: 12 | Issue: 5 | Pages: 611-621

10.2217/pmt-2022-0005 | PMID 35510333 Get It

Author response: P2RY14 cAMP signaling regulates Schwann cell precursor self-renewal, proliferation, and nerve tumor initiation in a mouse model of neurofibromatosis
Cram, Jennifer Patritti , Coover, Robert A. , Rizvi, Tilat A. , Chaney, Katherine E. , Ravindran, Ramya , Spinner, Robert J. , Wu, Jianqiang , Cancelas, José A. , Ratner, Nancy

Mayo Clinic

No container title available | March 28, 2022 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.7554/elife.73511.sa2 Get It

P2RY14 cAMP signaling regulates Schwann cell precursor self-renewal, proliferation, and nerve tumor initiation in a mouse model of neurofibromatosis
Cram, Jennifer Patritti , Wu, Jianqiang , Coover, Robert A, Rizvi, Tilat A, Chaney, Katherine E, Ravindran, Ramya, Cancelas, Jose A, Spinner, Robert J, Ratner, Nancy , Ravindran, Ramya , Patritti Cram, Jennifer , Wu, Jianqiang , Coover, Robert A, Rizvi, Tilat A, Chaney, Katherine E, Ravindran, Ramya, Cancelas, Jose A, Spinner, Robert J, Ratner, Nancy

Mayo Clinic

eLife | March 21, 2022 | Volume: 11 | Issue: No issue available | Pages: No page available

10.7554/elife.73511 | PMID 35311647 Get It

Neurofibromatosis type 1 (NF1) is characterized by nerve tumors called neurofibromas, in which Schwann cells (SCs) show deregulated RAS signaling. NF1 is also implicated in regulation of cAMP. We identified the G-protein-coupled receptor (GPCR) P2ry14 in human neurofibromas, neurofibroma-derived SC precursors (SCPs), mature SCs, and mouse SCPs. Mouse Nf1-/- SCP self-renewal was reduced by genetic or pharmacological inhibition of P2ry14. In a mouse model of NF1, genetic deletion of P2ry14 rescued low cAMP signaling, increased mouse survival, delayed neurofibroma initiation, and improved SC Remak bundles. P2ry14 signals via G i to increase intracellular cAMP, implicating P2ry14 as a key upstream regulator of cAMP. We found that elevation of cAMP by either blocking the degradation of cAMP or by using a P2ry14 inhibitor diminished NF1 -/- SCP self-renewal in vitro and neurofibroma SC proliferation in in vivo. These studies identify P2ry14 as a critical regulator of SCP self-renewal, SC proliferation, and neurofibroma initiation.
Factors Impacting the Success of Free Functioning Gracilis Muscle Transfer for Elbow Flexion in Brachial Plexus Reconstruction
Hinchcliff, Katharine M., Kircher, Michelle F., Bishop, Allen T., Spinner, Robert J., Shin, Alexander Y., Hinchcliff, Katharine M., Kircher, Michelle F., Bishop, Allen T., Spinner, Robert J., Shin, Alexander Y.

Mayo Clinic

Plastic & Reconstructive Surgery | March 10, 2022 | Volume: 149 | Issue: 5 | Pages: 921e-929e

10.1097/prs.0000000000009036 | PMID 35271536 Get It

Background: Free functioning muscle transfer is a reconstructive option to restore elbow flexion in brachial plexus injuries. The authors determined the impact of body mass index, age, and location of distal tendon attachment on elbow flexion strength after free functioning muscle transfer in traumatic brachial plexus injury patients. Methods: A retrospective review of patients who underwent free functioning muscle transfer for elbow flexion as part of their brachial plexus injury reconstruction with a minimum 2-year follow-up were evaluated. Outcomes assessed included elbow flexion strength (British Medical Research Council grade) and change in Disabilities of the Arm, Shoulder and Hand questionnaire and visual analogue scale pain scores. Results: One hundred six patients met inclusion criteria. The average age was 32 years, and the average body mass index was 27.1 kg/m2; 56.5 percent of patients achieved M3 or greater muscle grade using the authors’ strict modification of the British Medical Research Council scale. Disabilities of the Arm, Shoulder and Hand questionnaire scores improved from 45.7 to 38.8 (p < 0.05). Visual analogue scale pain scores decreased, but this trend did not obtain significance. Age and body mass index both had a significant negative impact on final free functioning muscle transfer grade (p < 0.05). Use of a distal tendon insertion led to improved muscle grade outcomes, with targeting of wrist extension being superior to finger flexion (p < 0.05). Simultaneous musculocutaneous nerve grafting did not significantly alter final elbow flexion strength. Conclusions: Increasing age and body mass index both imparted a deleterious effect on free functioning muscle transfer muscle grade. Distal muscle targets had better strength outcomes than when the biceps tendon was used. CLINICAL QUESTION/LEVEL OF EVIDENCE: Risk, III.